表紙
市場調査レポート

注入型ドラッグデリバリ関連の提携動向:条件・契約内容

Global Injectable Drug Delivery Partnering 2010-2016

発行 Current Partnering, a division of Wildwood Ventures Limited 商品コード 309767
出版日 ページ情報 英文 234 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
注入型ドラッグデリバリ関連の提携動向:条件・契約内容 Global Injectable Drug Delivery Partnering 2010-2016
出版日: 2016年04月04日 ページ情報: 英文 234 Pages
概要

当レポートでは、世界の注入型ドラッグデリバリ(注入型薬物送達)関連の企業提携(パートナーシップ)の締結動向やその内容(提携条件)について分析し、近年の企業提携の動向や特徴、平均的な取引条件、代表的な取引事例、大手製薬企業の契約動向、近年の提携取引一覧とその内訳(契約方式別・開発段階別・適応症別など)といった情報を盛り込んでお届けいたします。

エグゼクティブ・サマリー

第1章 イントロダクション

第2章 注入型ドラッグデリバリ関連の企業提携の傾向

  • イントロダクション
  • 近年の注入型ドラッグデリバリ関連の提携動向
  • 大手製薬企業による、注入型ドラッグデリバリ関連の提携活動
  • 大手バイオテクノロジー企業による、注入型ドラッグデリバリ関連の提携活動
  • 注入型ドラッグデリバリ関連の提携:契約の種類別
  • 注入型ドラッグデリバリ関連の提携:業種別
  • 注入型ドラッグデリバリ関連の提携:治験段階別
  • 注入型ドラッグデリバリ関連の提携:治療法の種類別
  • 公開されている資本取引の条件
    • 支払総額
    • 前払い金
    • マイルストーン払い
    • ロイヤルティ料率

第3章 注入型ドラッグデリバリ関連の代表的な資本取引

  • イントロダクション
  • 注入型ドラッグデリバリ関連の代表的な資本取引と取引金額

第4章 注入型ドラッグデリバリ関連の提携契約の一覧

  • イントロダクション
  • 企業名順(A〜Z)
  • 取引の種類別
    • 資産購入
    • 大手製薬企業のアウトライセンス
    • 共同開発
    • 共同研究開発(R&D)
    • 共同販売
    • 契約サービス
    • 共同プロモーション
    • 共同研究開発合意(CRADA)
    • クロスライセンス
    • 開発
    • 流通
    • 株式購入
    • 評価
    • 助成金
    • 合弁事業
    • ライセンス
    • 製造
    • マーケティング
    • オプション
    • プロモーション
    • 研究
    • 調停
    • スピンアウト
    • 二次ライセンス
    • 供給
    • 契約終了
  • 業種別
    • 学術機関
    • 大手製薬企業
    • バイオテクノロジー企業
    • ドラッグデリバリ
    • 医療機器
    • 診断企業
    • ジェネリック医薬品企業
    • 政府
    • 非営利組織
    • 医薬品企業
    • 研究ツール
    • 医療サービス
    • 特殊医薬品
  • 治験段階別
    • 創薬
    • 前臨床
    • 第I相
    • 第II相
    • 第III相
    • 認証中
    • 上市済み
  • 治療の種類別
    • 心血管疾患
    • 中枢神経系(CNS)疾患
    • 歯科
    • 皮膚疾患
    • 胃腸障害
    • 遺伝子疾患
    • 尿生殖器疾患
    • 婦人科
    • 血液疾患
    • 入院治療
    • 免疫疾患
    • 感染症
    • 代謝障害・内分泌障害
    • 筋骨格系疾患
    • 産科
    • 奇病
    • 腫瘍
    • 眼科
    • 小児科
    • 精神疾患
    • 公衆衛生
    • リハビリ医学
    • 呼吸器疾患
    • 感覚器
    • 性と生殖に関する健康

第5章 提携リソースセンター

  • オンライン・パートナーリング
  • パートナーリングの動向
  • 関連資料

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: CP2102inj

‘Injectable Drug Delivery Partnering 2010-2015’ report provides understanding and access to the injectable drug delivery partnering deals and agreements entered into by the world's leading healthcare companies.

  • Trends in injectable drug delivery partnering deals
  • Top injectable drug delivery deals by value
  • Deals listed by company A-Z, deal type, stage of development, therapy type

This report provides details of the latest Injectable Drug Delivery agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Injectable Drug Delivery deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Injectable Drug Delivery partnering deals.

The report presents financial deal term values for Injectable Drug Delivery deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Injectable Drug Delivery partnering field; both the leading deal values and most active Injectable Drug Delivery dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 280 online deal records of actual Injectable Drug Delivery deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Injectable Drug Delivery dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Injectable Drug Delivery dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Injectable Drug Delivery deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Injectable Drug Delivery dealmaking with a brief summary followed by a comprehensive listing of Injectable Drug Delivery deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Injectable Drug Delivery partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Injectable Drug Delivery partnering deals signed and announced since Jan 2010. The chapter is organized by specific Injectable Drug Delivery technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Injectable Drug Delivery partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Injectable Drug Delivery partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Injectable Drug Delivery technologies and products.

Key benefits

‘Global Injectable Drug Delivery Partnering 2010-2016: Deal trends, players, financials and forecasts’ provides the reader with the following key benefits:

  • In-depth understanding of Injectable Drug Delivery deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Injectable Drug Delivery agreements with numerous real life case studies
  • Detailed access to actual Injectable Drug Delivery contracts entered into by leading biopharma companies
  • Identify most active Injectable Drug Delivery dealmakers since 2010
  • Insight into terms included in a Injectable Drug Delivery partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

‘Global Injectable Drug Delivery Partnering 2010-2016: Deal trends, players, financials and forecasts’ is intended to provide the reader with an in-depth understanding and access to Injectable Drug Delivery trends and structure of deals entered into by leading companies worldwide.

Injectable Drug Delivery Partnering Terms and Agreements includes:

  • Trends in Injectable Drug Delivery dealmaking in the biopharma industry since 2010
  • Analysis of Injectable Drug Delivery deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Injectable Drug Delivery deals
  • Access to Injectable Drug Delivery contract documents
  • Leading Injectable Drug Delivery deals by value since 2010
  • Most active Injectable Drug Delivery dealmakers since 2010

In ‘Global Injectable Drug Delivery Partnering 2010-2016: Deal trends, players, financials and forecasts’, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The ‘Global Injectable Drug Delivery Partnering 2010-2016: Deal trends, players, financials and forecasts’ report provides comprehensive access to available deals and contract documents for over 280 Injectable Drug Delivery deals.

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Injectable Drug Delivery dealmaking

  • 2.1. Introduction
  • 2.2. Injectable Drug Delivery partnering over the years
  • 2.3. Most active Injectable Drug Delivery dealmakers
  • 2.4. Injectable Drug Delivery partnering by deal type
  • 2.5. Injectable Drug Delivery partnering by therapy area
  • 2.6. Deal terms for Injectable Drug Delivery partnering
    • 2.6.1. Injectable Drug Delivery partnering headline values
    • 2.6.2. Injectable Drug Delivery deal upfront payments7
    • 2.6.3. Injectable Drug Delivery deal milestone payments
    • 2.6.4. Injectable Drug Delivery royalty rates

Chapter 3 - Leading Injectable Drug Delivery deals

  • 3.1. Introduction
  • 3.2. Top Injectable Drug Delivery deals by value

Chapter 4 - Most active Injectable Drug Delivery dealmakers

  • 4.1. Introduction
  • 4.2. Most active Injectable Drug Delivery dealmakers
  • 4.3. Most active Injectable Drug Delivery partnering company profiles

Chapter 5 - Injectable Drug Delivery contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Injectable Drug Delivery contracts dealmaking directory

Chapter 6 - Injectable Drug Delivery dealmaking by technology type

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

Appendix 1 - Injectable Drug Delivery deals by company A-Z

Appendix 2 - Injectable Drug Delivery deals by stage of development

  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Regulatory
  • Marketed
  • Formulation

Appendix 3 - Injectable Drug Delivery deals by deal type

  • Asset purchase
  • Assignment
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Co-market
  • Co-promotion
  • CRADA
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Litigation
  • Manufacturing
  • Marketing
  • Material transfer
  • Option
  • Promotion
  • Research
  • Settlement
  • Spin out
  • Sub-license
  • Supply
  • Technology transfer
  • Termination
  • Warranty

Appendix 4 - Injectable Drug Delivery deals by therapy area

Appendix 5 -Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Injectable Drug Delivery partnering since 2010
  • Figure 2: Active Injectable Drug Delivery dealmaking activity- 2010 to 2016
  • Figure 3: Injectable Drug Delivery partnering by deal type since 2010
  • Figure 4: Injectable Drug Delivery partnering by disease type since 2010
  • Figure 5: Injectable Drug Delivery deals with a headline value
  • Figure 6: Injectable Drug Delivery deals with an upfront value
  • Figure 7: Injectable Drug Delivery deals with a milestone value
  • Figure 8: Injectable Drug Delivery deals with a royalty rate value
  • Figure 9: Top Injectable Drug Delivery deals by value since 2010
  • Figure 10: Most active Injectable Drug Delivery dealmakers 2010 to 2016
  • Figure 11: Online partnering resources
  • Figure 12: Forthcoming partnering events
Back to Top